Guillermo Sanz

Research interests

Publications

• Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

  NEJM Evidence · 2022 · https://doi.org/10.1056/evidoa2200008

• Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes

  Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.20.01659

• Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

  Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-1008-z

• Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

  Blood · 2017 · https://doi.org/10.1182/blood-2016-06-724500

• Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia

  Blood · 2016 · https://doi.org/10.1182/blood-2016-05-714030

• Time-dependent changes in mortality and transformation risk in MDS

  Blood · 2016 · https://doi.org/10.1182/blood-2016-02-700054

• An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

  Blood · 2015 · https://doi.org/10.1182/blood-2014-10-607341

• Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)

  Leukemia · 2015 · https://doi.org/10.1038/leu.2015.55

• Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

  Blood · 2013 · https://doi.org/10.1182/blood-2013-03-492884

• Revised International Prognostic Scoring System for Myelodysplastic Syndromes

  Blood · 2012 · https://doi.org/10.1182/blood-2012-03-420489

• A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

  Blood · 2011 · https://doi.org/10.1182/blood-2011-01-330126

• Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes

  Cancer · 2011 · https://doi.org/10.1002/cncr.25774

• Cytogenetic risk stratification in chronic myelomonocytic leukemia

  Haematologica · 2010 · https://doi.org/10.3324/haematol.2010.030957

• Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2009.23.8329

• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

  The Lancet Oncology · 2009 · https://doi.org/10.1016/s1470-2045(09)70003-8

• Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

  Cancer · 2008 · https://doi.org/10.1002/cncr.23697

• Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model

  Haematologica · 2007 · https://doi.org/10.3324/haematol.11575

• Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.

  PubMed · 2005

• Factors associated with outcomes of unrelated cord blood transplant: Guidelines for donor choice

  Experimental Hematology · 2004 · https://doi.org/10.1016/j.exphem.2004.01.002

• Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies

  Blood · 2001 · https://doi.org/10.1182/blood.v98.8.2332

• Report of an international working group to standardize response criteria for myelodysplastic syndromes.

  PubMed · 2000

Current projects

No projects listed.